Avenue Therapeutics, Inc.
ATXI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001644963
No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Avenue Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 19 | 11 | −8 |
| SharesConverted for a 1-for-15 split | 45.0K | 75.9K | +31.0K (+68.8%) |
| Value | $181.0K | $766.0K | +$585.0K (+323.2%) |
New holders (4)
Institutions that held Avenue Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 35,865 | $362.0K | 0.00% |
| Two Sigma Investments, LP | 14,342 | $145.0K | 0.00% |
| Morgan Stanley | 1,474 | $15.0K | 0.00% |
| Bank of America Corp | 1 | $0 | 0.00% |
Sold out (12)
Institutions that held Avenue Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Vanguard Group Inc | 131,569 | $36.0K |
| Renaissance Technologies LLC | 124,400 | $34.0K |
| Geode Capital Management, LLC | 84,033 | $22.0K |
| National Asset Management, Inc. | 58,330 | $16.0K |
| HRT Financial LP | 39,100 | $10.0K |
| Susquehanna International Group, LLP | 25,707 | $7.00K |
| Northern Trust Corp | 13,767 | $4.00K |
| Millennium Management LLC | 11,247 | $3.00K |
| Cetera Advisor Networks LLC | 11,392 | $3.00K |
| BNP Paribas Arbitrage, SA | 8 | $2 |
| JPMorgan Chase & Co | 1 | $0 |
| Royal Bank of Canada | 132 | $0 |